Workflow
J&J(JNJ)
icon
Search documents
X @Bloomberg
Bloomberg· 2025-10-07 19:02
Johnson & Johnson was told by a California jury to pay $966 million to the family of a deceased woman who blamed her cancer on life-long use of the company’s baby powder in the largest verdict for a single user in the 15-year litigation. https://t.co/SnXMLNhmqL ...
Johnson & Johnson ordered to pay $966 million in talc cancer case after jury finds company liable
The Economic Times· 2025-10-07 18:20
The family of The verdict could be reduced on appeal as the Erik Haas, Johnson & Johnson's worldwide vice president of litigation, said in a statement that the company plans to immediately appeal, calling the verdict "egregious and unconstitutional." "The plaintiff lawyers in this Moore case based their arguments on 'junk science' that never should have been presented to the jury," Haas said.Live Events The company has said its products are safe, do not contain asbestos, and do not cause cancer. J&J stop ...
J&J Must Pay $966M After LA Jury Finds Company Liable In Talc Cancer Case
Insurance Journal· 2025-10-07 15:53
A Los Angeles jury late on Monday ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest lawsuit alleging its baby powder products cause cancer.The family of Mae Moore, who died in 2021, sued the company the same year, claiming Johnson & Johnson’s talc baby powder products contained asbestos fibers that caused her rare cancer. The jury ordered the company to pay $16 million in compensatory damages and $950 million in puniti ...
Johnson & Johnson ordered to pay $966 million after jury finds company liable in talc cancer case
Reuters· 2025-10-07 14:50
A Los Angeles jury late on Monday ordered Johnson & Johnson to pay $966 million to the family of a woman who died from mesothelioma, finding the company liable in the latest lawsuit alleging its baby ... ...
Market Movers: IBM, AMD Surge on AI Deals; J&J Reports Positive Drug Data; BofA Shifts Sector Outlook; Mercedes-Benz Sales Dip
Stock Market News· 2025-10-07 12:38
Key TakeawaysIBM (IBM) and Advanced Micro Devices (AMD) led pre-market gains, with IBM rising 4.3% on a strategic partnership with Anthropic and AMD surging 4% after a Jefferies upgrade to a $300 price target following a significant OpenAI deal.Johnson & Johnson (JNJ) announced positive Phase 2b study results for its investigational oral drug icotrokinra in ulcerative colitis, demonstrating a 63.5% clinical response rate at the highest dose, and reaffirmed the known safety record of its drug Tremfya.BofA Gl ...
强生股价盘前下跌2.5%
Mei Ri Jing Ji Xin Wen· 2025-10-07 12:33
每经AI快讯,10月7日,强生股价盘前下跌2.5%。 (文章来源:每日经济新闻) ...
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
Prnewswire· 2025-10-07 12:05
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12 in the Phase 2b ANTHEM-UC study These data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor as a potential new option for people with moderately to severely active ulcerative colitis , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)Â today announced additional Week 12 results from t ...
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
Prnewswire· 2025-10-07 12:05
Patients treated with subcutaneous TREMFYAachieved clinically meaningful results in both clinical remission (36.7%) and endoscopic remission (25.9%) at Week 48 in the Phase 3 ASTRO study Clinical and endoscopic outcomes were demonstrated across both biologic-naïve and biologic-refractory sub- groups TREMFYA Â is the only IL-23 inhibitor with a fully subcutaneous regimen, following recent FDA approval of SC induction in adults with ulcerative colitis , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today anno ...
Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
MarketBeat· 2025-10-06 18:21
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue. With increased volume and demand, suppliers also receive better deals, which significantly lower costs, among other benefits. Ultimately, a price discou ...
These Trump voters are wary of COVID shots, but don't want RFK to restrict other vaccines
The Economic Times· 2025-10-06 14:26
A mercury-containing preservative that is used in some vaccines has not been used in childhood vaccines since 2001, according to the Despite his concerns about childhood vaccines, Hill would not support new restrictions on them while more research is conducted. "If there are people that want it, I think it should be available to them," said Hill, a supervisor at a nuclear power plant. "While you're studying, let be available." Hill is one of 20 Americans who voted for President Donald Still, each of thes ...